RxDoctor Payments Data

Sadhna Rastogi, MD

Internal Medicine · North Bergen, NJNPI 1699714436

Payments from drug & device makers

$2,778in general payments, 2019–2025

Across 134 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$610
  • Merck$495
  • AbbVie$255
  • Boehringer Ingelheim$246
  • Johnson & Johnson$187
  • Novo Nordisk$176
  • plus $809 from 10 others

What the payments were for

  • Food & beverage$2,67696%
  • Education$1014%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,778 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$67,918
Medicare patients
150
Services billed
761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala54$281,098
DovatoDolutegravir Sodium/Lamivudine26$71,530
OdefseyEmtricitab/Rilpiviri/Tenof Ala16$56,997
EliquisApixaban120$53,596
JardianceEmpagliflozin51$37,906
OzempicSemaglutide23$32,743
XareltoRivaroxaban173$30,207
TivicayDolutegravir Sodium12$24,957
ProcritEpoetin Alfa20$16,742
JanuviaSitagliptin Phosphate18$14,848
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$13,380
FarxigaDapagliflozin Propanediol12$12,008
SantylCollagenase Clostridium Hist.16$10,593
Atorvastatin Calcium545$3,763
ShingrixVaricella-Zoster Ge/As01b/Pf16$3,520

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$610$281,09854 claims
Viiv Healthcare CompanyDovato, Tivicay$136$96,48738 claims
PfizerEliquis$135$53,596120 claims
Johnson & JohnsonXarelto, Procrit$187$46,949193 claims
Boehringer IngelheimJardiance$246$37,90651 claims
Novo NordiskOzempic$176$32,74323 claims
GSKTrelegy Ellipta, Shingrix$131$16,90037 claims
MerckJanuvia$495$14,84818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in North Bergen

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →